Lu AF28996 in Participants With Parkinson's Disease (PD)
← catalyst calendarSponsored by H. Lundbeck A/S (industry) · HLUN-B.CO — their whole pipeline →.
Phase
Phase 1
Status
Completed
Study type
Interventional
Design
Na · None · Treatment
Enrollment
57actual
Sites
15
Countries
France, Germany, Netherlands +2
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2020-02-26 | actual | When the study began enrolling |
| Primary completion | 2025-10-14 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-02-12 | actual | The whole study's end, after follow-up |
| First posted | 2020-03-02 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-03-06 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Parkinson Disease
Intervention
- Drug: Lu AF28996
Primary outcomes
what the primary-completion date above is the date OFNumber of Participants with Treatment-emergent Adverse Events
measured From Baseline to 5.5 Months
Cmax of Lu AF28996
measured 0 (predose) to 24 hours postdose on Day 1 to Day 47
Tmax of Lu AF28996
measured 0 (predose) to 24 hours postdose on Day 1 to Day 47
Permalink · HLUN-B.CO's whole pipeline · Catalyst calendar · Every registered study · What changed